Dr. Glaser is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 health plaza
East Hanover, NJ 07936Phone+1 610-247-4906
Summary
- I am a board certified interventional cardiologist with a masters in clinical epidemiology and biostatistics. I spent 14 years at the hospital of the University of Pennsylvania with the last 8 as associate professor of medicine, cardiovascular division. I specialized in both ACS research and structural heart disease. I then transitioned to a full time research career first at GSK as head of Clinical
sciences where I led the clinical
Development organization for pharmaceuticals and then Moderna. I currently am Global Head of Clinical Development across all the portfolio at Novartis, a top 5 global pharma company. I am responsible for the development phase and clinical trials of all Novartis medicines in development
Education & Training
- University of PennsylvaniaM.S., Clinical Epidemiology and Biostatistics, 2002 - 2008
- University of Pennsylvania Health SystemFellowship, Interventional Cardiology, 2002 - 2003
- University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 1999 - 2002
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 1999
- Weill Cornell MedicineClass of 1996, MD, Alpha Omega Alpha
- Cornell UniversityBS, Neurobiology and behavior , 1988 - 1992
- Cornell UniversityB.S., 1988 - 1992
Certifications & Licensure
- PA State Medical License 1999 - 2016
- DE State Medical License Active through 2013
Awards, Honors, & Recognition
- Cardiovascular Fellow Research Award University of Pennsylvania Medical Center, 2002
- Alpha Omega Alpha Honor Society Cornell University Medical College, 1996
- David Drusin Memorial Award for Excellence in Medicine Cornell University Medical College, 1996
- Join now to see all
Clinical Trials
- Outpatient Percutaneous Coronary Intervention Start of enrollment: 2004 Aug 01
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) Start of enrollment: 2014 Jun 03
Publications & Presentations
PubMed
- Retrospective study of propionic acidemia using natural language processing in Mayo Clinic electronic health record data.Hannah Barman, Vanja Sikirica, Katherine Carlson, Eli Silvert, Katherine Brewer Carlson
Molecular Genetics and Metabolism. 2023-11-01 - 173 citationsEffect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.Michelle L. O'Donoghue, Ruchira Glaser, Matthew A. Cavender, Philip E. Aylward, Marc P. Bonaca
JAMA. 2016-04-19 - 144 citationsSubretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments TrialsAlex S. Willoughby, Gui-Shuang Ying, Cynthia A. Toth, Maureen G. Maguire, Russell Burns
Ophthalmology. 2015-09-01
Journal Articles
- Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments TrialsSharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research ..., Ophthalmology, 1/1/2016
- Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments TrialsShah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research ..., Ophthalmology, 1/1/2016
- Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical TrialO'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ..., JAMA, 1/1/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Women With ST Elevation Myocardial Infarction Treated With Primary PCI Have Worse Outcomes Than Men in the Modern Era: Results From the APEX-AMI Trial.Glaser, R, Kaul, P, Roberts, R, Armstrong, PW, Granger, CB, Berdan, LG, Hochman, J, White, Mahaffey, KW, Circulation, 1/1/2009
- A Comparison of Drug-Eluting and Bare-Metal Stents for Saphenous Vein Graft Lesions: A Report From the National Heart, Lung, and Blood Institute Dynamic Registry 2806-4Drew E. Baldwin, Jeffrey C. Trost, J. Dawn Abbott, Helen Vlachos, Ruchira Glaser, Robert L. Wilensky, James N. Slater, Nirat Beohar, David O. Williams, JACC, 1/1/2008
- Underutilization of Clopidogrel Pre-treatment in the NHLBI Dynamic PCI Registry: A Missed Opportunity?Herbert D. Aronow, Ruchira Glaser, Faith Selzer, J. Dawn Abbott, David O. Williams, Timothy A. Shapiro, Kevin E. Kip, Sheryl F. Kelsey, JACC, 1/1/2008
- Join now to see all
Lectures
- Management of Stable Coronary Artery Disease Patient.Philadelphia, PA - 1/25/2009
- Women With ST Elevation Myocardial Infarction Treated With Primary PCI Have Worse Outcomes Than Men in the Modern Era: Results From the APEX-AMI TrialOrlando, FL - 1/16/2009
- Coronary Revascularization in Women.Rockport, ME - 1/13/2005
- Join now to see all
Other
- Percutaneous Coronary Intervention in Women.Ananostopoulos, AM, Glaser, R, Business Briefing: Women's Healthcare
1/1/2005 - Myocardial Infarction in Women. (Interview)Glaser R, ACCEL Educational Series
New Orleans, LA - 1/1/2004 - Women Treated by PCI for ACS Have Worse Outcomes than Men. (Interview)Glaser R, American Heart Association News
New Orleans, LA - 1/1/2004 - Join now to see all
Press Mentions
- Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic AcidemiaAugust 16th, 2021
- Patients in NC File Antitrust Suit Against HCA HealthcareAugust 12th, 2021
- Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease VaccinesJanuary 11th, 2021
Professional Memberships
- Fellow
- Member
- Fellow
Industry Relationships
- Senior Vice President, Moderna2021 - Present
- Vice President R&D, GlaxoSmithKline2010 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: